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Abstract 
Introduction: Glycemic variability (GV) represents the amplitude of oscillations in glucose levels over time and is 
associated with higher mortality in critically ill patients. Our aim is to evaluate the impact of GV on acute ischemic 
stroke (IS) outcomes in humans and explore the impact of two different insulin administration routes on GV in an 
animal model.
Methods: This translational study consists of two studies conducted in parallel: The first study is an observational, 
multicenter, prospective clinical study in which 340 patients with acute IS will be subcutaneously implanted a sen‑
sor to continuously monitor blood glucose levels for 96 h. The second study is a basic experimental study using an 
animal model (rats) with permanent occlusion of the middle cerebral artery and induced hyperglycemia (through an 
intraperitoneal injection of nicotinamide and streptozotocin). The animal study will include the following 6 groups 
(10 animals per group): sham; hyperglycemia without IS; IS without hyperglycemia; IS and hyperglycemia without 
treatment; IS and hyperglycemia and intravenous insulin; and IS and hyperglycemia and subcutaneous insulin. The 
endpoint for the first study is mortality at 3 months, while the endpoints for the animal model study are GV, functional 
recovery and biomarkers.
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Introduction
Glycemic variability (GV) represents the amplitude of 
oscillations in blood glucose levels over time and has 
been associated with higher mortality and poor outcomes 
in critically ill patients [1, 2]. Few studies have evaluated 
the prognostic influence of GV in patients with acute 
ischemic stroke (IS) [3–8]; however, it has been suggested 
that GV is an even more powerful prognostic factor than 
poststroke hyperglycemia [9, 10]. Recently, the GLIAS-
II study found higher GV in patients with acute IS who 
were considered nonresponders to conventional correc-
tive treatment for hyperglycemia [11].
However, the factors influencing the development of 
wider GV in acute IS remain unknown. The use of slid-
ing-scale subcutaneous insulin every 4–6 h has been sug-
gested to be associated with large oscillations in blood 
glucose levels and, consequently, to higher GV [12]. Simi-
larly, intensive intravenous insulin therapy has shown 
higher GV than standard treatment [6] and could explain 
the trend towards higher mortality in clinical trials aimed 
at a tight reduction in blood glucose levels in acute stroke 
[3].
One of the limitations of previous studies that evalu-
ated GV is that it was measured with intermittent read-
ings of blood glucose levels [5, 13], with inconsistent 
numbers of blood glucose measurements [14]. The devel-
opment of continuous glucose monitors (CGM) [15, 16] 
has provided an opportunity for exploring the prognostic 
effect of GV in acute IS and those factors that affect the 
oscillations in blood glucose levels during the first days 
following a stroke.
We hypothesized that GV, assessable by means of con-
tinuous subcutaneous monitoring devices, could act 
as a powerful prognostic predictor of mortality, possi-
bly higher than assessment of mean or maximum blood 
glucose levels and that the different treatment regimens 
used in routine clinical practice could modify glycemic 
variability. Our aim is to evaluate the impact of GV on IS 
outcomes and examine the impact of two different insu-
lin administration routes on GV in an animal model of IS.
Methods
The translational study consists of a multicenter observa-
tional study that will include patients with acute IS and a 
parallel basic experimental study using an animal model.
Design
Clinical study
Observational, multicenter, prospective study.
Patient population The inclusion and exclusion criteria 
are listed in Table 1.
Randomization None (observational study).
Intervention After the participants sign the informed 
consent form, they will be implanted a CGM subcutane-
ously to monitor glucose levels for 96  h. These devices 
are of common use in the management of type 1 diabetes 
and they have been proven to be safe in stroke patients 
when used in research studies. Capillary finger prick glu-
cose levels will be recorded every 4–6 h according to the 
standard protocols of each center, as well as the insulin 
administration characteristics (type, dose and route of 
administration) as per the treating physician’s criteria, fol-
lowing the local protocols for the in-hospital management 
of hyperglycemia. The treating physician and the nursing 
personnel will be blinded to the readings taken by the 
CMG device. All study centers will use the same brand of 
CGM (CE-marked). All patients will be managed accord-
ing to current guidelines for acute stroke management 
and local protocols, including treatment with intravenous 
thrombolysis or mechanical thrombectomy if applicable. 
No laboratory data other than HbA1c will be collected for 
Discussion: The GLIAS‑III study will be the first translational approach analyzing the prognostic influence of GV, 
evaluated by the use of subcutaneous glucose monitors, in acute stroke.
Trial registration https ://www.clini caltr ials.gov (NCT04001049)
Keywords: Ischemic stroke, Glycemic variability, Insulin, Outcomes, Translational research
Table 1 GLIAS-III main inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
Male and female patients older than 18 years, with acute IS
Inclusion in the study within the first 24 h of stroke onset
A prestroke score on the Modified Rankin Scale (mRS) ≤ 1
Signed informed consent
Transient ischemic attack
Predicted need for an MRI within the first 96 h after inclusion
A health status, clinical condition or other characteristic that precludes appropriate 
diagnosis, treatment, or follow‑up in the trial
Current drug or alcohol use dependence
Participation in a therapeutic clinical trial
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the study proposal. Any emergent laboratory abnormality 
during the study follow-up will be recorded as a complica-
tion.
Study schedule The study will last 3 months per patient 
according to the schedule shown in Table 2.
Primary endpoints 
• GV. Defined as the standard deviation of the mean 
blood glucose level for each patient [17]. For the main 
analysis, we will use the GV value recorded within 
the first 48 h after stroke onset. We will conduct an 
exploratory analysis to evaluate the GV between 48 
and 96 h.
• Mortality: in-hospital and at 3 months.
Secondary endpoints 
• Modified Rankin Scale (mRS) and National Institutes 
of Health Stroke Scale. (NIHSS) at 3 months. These 
scales will be evaluated by a neurologist blinded to 
the GV values.
• Other GV measurements: coefficient of varia-
tion (CV), mean amplitude of glycemic excursions 
(MAGE); mean absolute glucose (MAG) rate of 
change [2, 17, 18]. CV is less influenced by mean 
glucose and is a good marker of hypoglycemia. A 
threshold value to define low and high GV using CV 
has recently been proposed [19]. MAGE and MAG 
are indexes used for studying glycemic variability in 
clinical trials, and normal references values for peo-
ple without diabetes using CGM are available [18]. 
On the other hand, MAGE can provide information 
about the influence of the largest glycemic excur-
sions.
• Neurological or systemic complications during 
follow-up. The following complications are pre-
specified by protocol and will be checked at each 
visit: coma, seizures, early neurological impairment, 
brain edema, hemorrhagic transformation, recur-
rent strokes, acute coronary syndrome, pulmonary 
thromboembolism, respiratory infection, urinary 
infection, sepsis. Any other non-pre-specified com-
plication reported during follow-up will be also 
recorded.
Data collection and management In addition to the pri-
mary and secondary endpoints, the following data will be 
collected:
• Demographic data and risk factors: age, sex, race, 
weight, height, diabetes, hypertension, dyslipidemia, 
coronary arterial disease, atrial fibrillation, metabolic 
syndrome, chronic renal disease (eGFR of less than 
60 ml/min/1.73m2), tobacco use and alcohol abuse.
• Pre-stroke pharmacological treatments: antiplatelets, 
anticoagulants, blood-pressure lowering drugs, anti-
diabetics and hypolipemiants.
Table 2 GLIAS-III flow diagram
HbA1c glycated hemoglobin, NIHSS, National Institutes of Health Stroke Scale
Baseline 96 h (± 6 h) Day 7 
or discharge 
(± 1 d)
Day 30 (± 2 d) Day 90 
(± 3 d)
Signed informed consent X
Inclusion/exclusion criteria review X
Past medical/surgical history x
Pre‑stroke treatments x
Modified rankin scale (Pre‑stroke) X X X
NIHSS X X X X X
Reperfusion treatment received X
HbA1c X X
Continuous blood glucose monitoring  < –––––––––––––– > 
Capillary glucose levels (per local protocols)  < –––––––––––––– > 
Insulin (type, dosage and route) administered 
according to local protocols
 < –––––––––––––– > 
Systemic and neurological complications  < ––––––––––––––––––––––––––––––––––––––––– > 
Stroke etiological subtype X
Secondary stroke prevention treatments X X X
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• Stroke data: stroke severity on admission (NIHSS), 
date of stroke onset (or last time known asympto-
matic in those patients with unknown stroke onset), 
stroke etiological subtype, treatment with intrave-
nous thrombolysis or mechanical thrombectomy.
• Vital signs at baseline visit: body temperature, blood 
pressure, heart rate, respiratory rate.
Data will be prospectively included in a study-specific 
web-based database developed and managed by the Clin-
ical Trials Unit at Hospital 12 de Octubre which belongs 
to the Spanish Clinical Research Network (SCReN), 
independent form the study sponsor. All data manage-
ment will follow the principles of the European regula-
tions for biomedical research ensuring confidentiality. 
In compliance with European regulations/International 
Conference of Harmonization Good Clinical Prac-
tice Guidelines, the investigator and the institution are 
required to permit direct access to authorized repre-
sentatives of the Ethics Committee to review the subject’s 
original medical records for verification of study-related 
procedures and data.
Data monitoring body Monitoring will be conducted 
by dedicated personnel at La Paz University Hospital. All 
data management will follow the principles of the Euro-
pean regulations for biomedical research, ensuring the 
confidentiality of all personal data. In compliance with 
European regulations/International Conference of Har-
monization Good Clinical Practice (ICHGCP) Guidelines, 
the investigator and institution are required to permit 
authorized representatives of the regulatory agency(s), 
and the IEC/IRB direct access to review the subject’s 
original medical records for verification of study-related 
procedures and data.
Sample size estimates Based on the data from the 
GLIAS-II study, [11] conducted in a similar setting and 
using nQuery Advisor software (Statistical Solutions Ltd., 
Cork, Ireland), we calculated that a sample of 340 patients 
will be required to achieve 80% statistical power and a 
confidence level alpha of 0.05 to detect a significant effect 
of GV on mortality at 3 months.
Recruiting hospitals Hospital Universitario La Paz 
(Madrid), Hospital Universitario 12 de Octubre (Madrid), 
Hospital Universitario A Coruña (A Coruña), Hospital 
Universitario de Santiago de Compostela (Santiago de 
Compostela), Hospital de Donostia (San Sebastián), Hos-
pital Universitario Cruces (Bizkaia), Complejo Hospita-
lario de Navarra (Pamplona), Hospital de la Santa Creu 
i San Pau (Barcelona), Hospital Clínico Universitario de 
Valladolid (Valladolid) and Hospital San Pedro de Alcán-
tara (Cáceres).
Experimental animal model of stroke and hyperglycemia 
in rats
The basic experimental study will use an animal model 
of permanent middle cerebral artery occlusion (MCAO) 
and hyperglycemia in rats. The experiments are designed 
to minimize animal suffering in compliance with our 
Ethical Committee for the Care and Use of Animals in 
Research (EU directives 86/609/CEE and 2003/65/CE).
Study groups A total of 60 Sprague–Dawley rats 
(8–9  weeks old, weighing 200–250  g) will be randomly 
assigned to the following groups:
1. Sham: hyperglycemia and surgery without MCAO.
2. Non-stroke group: hyperglycemia without MCAO.
3. Normoglycemic group: normoglycemia with MCAO.
4. Non-treated hyperglycemic group: hyperglycemia 
with MCAO.
5. Intravenously treated hyperglycemic group: Hyper-
glycemia with MCAO and intravenous insulin 
administration (dosage, 3 U/day).
6. Subcutaneously treated hyperglycemic group: Hyper-
glycemia with MCAO and subcutaneous insulin 
administration (dosage, 3 U/day).
Randomization We will follow RIGOR recommenda-
tions for animal research in terms of randomization and 
blinded study [20]. Each rat will be sequentially assigned to 
a study group based on the randomization plan. To main-
tain the blinding during the course of the study, we will 
ensure that the researcher who evaluates the endpoints 
and performs the laboratory analyses will not have access 
to the randomization codes, and a different researcher will 
perform the surgery, hyperglycemia induction and insulin 
administration. Following the STAIR recommendations, 
both female and male rats will be included (1:1 ratio) [21]. 
The stage of estrous cycle will be recorded. If variability is 
observed in the final results, a specific post-hoc analysis of 
the estrous cycle stage will be performed.
Intervention Hyperglycemia will be induced by an intra-
peritoneal injection of nicotinamide (210  mg/kg) (EMD 
Millipore, Germany). Fifteen minutes later, an intraperi-
toneal injection of streptozotocin (60 mg/kg) (EMD Mil-
lipore, Germany) will be administered [22, 23]. Blood 
glucose levels will then be measured using a glucometer 
(ACCU-CHEK, Performa, Germany) for 72  h. The ani-
mals with a blood glucose level > 250 mg/dL will be con-
sidered hyperglycemic [23].
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To induce a stroke, the rats will be anesthetized via 
an intraperitoneal injection of a solution of ketamine 
(25  mg/kg) and diazepam (2  mg/kg). Analgesia will be 
induced with a subcutaneous injection of meloxicam 
(2  mg/kg). To perform the MCAO, a small craniotomy 
will be performed, and the right middle cerebral artery 
will be permanently ligated just before its bifurcation. 
Both common carotid arteries will then be occluded for 
60 min, as previously described [24]. A device for CGM 
will then be implanted subcutaneously for at least 96 h.
Insulin treatment will be administered 4 h after MCAO 
and until 96  h later. The administration will be intrave-
nous or subcutaneous, depending on the experimental 
group. The dosage per animal (3 U/day) has been deter-
mined based on the results of a previous dose–response 
study [23].
Study schedule The study will last a total of 31 days for 
each rat, according to the schedule illustrated in Fig. 1.
Primary endpoint 
• GV, defined as the standard deviation of the mean 
glucose level [17]. We will analyze whether the insu-
lin administration route (intravenous and subcutane-
ous) affects the GV.
Secondary endpoints 
• Functional evaluation, analyzed by a researcher 
blinded to the experimental groups, at 24 h, 1 week 
and 4 weeks post-stroke. Motor and sensory perfor-
mance will be evaluated using a variant of Rogers’ 
functional scale [23]. The beam walking test will eval-
uate hindlimb functions by testing the rats’ ability to 
traverse a wooden beam [23].
• Lesion size will be analyzed at 24 h and 4 weeks post-
stroke by 7-T horizontal bore magnetic resonance 
imaging (MRI) (Bruker PharmaScan, Ettlingen, Ger-
many), using T2-weighted (T2-W) spin-echo ana-
tomical images, by a researcher who will be blinded 
to the experimental groups.
• Brain damage and repair-related markers will be 
analyzed at 4  weeks. The perilesional area of the 
brain will be studied in detail using immunofluores-
cence for superoxide dismutase 2, catalase, vascular 
endothelial growth factor (VEGF), brain-derived 
neurotrophic factor (BDNF), synaptophysin, glial 
fibrillary acidic protein, myelin basic protein and 
oligodendrocyte. Immunofluorescence images will 
be acquired by a researcher (who will be blinded to 
the experimental groups) using a Leica TCS-SPE 
confocal microscope (Leica Microsystems, Heidel-
berg, Germany). Plasma levels of damage and repair 
markers will be studied using Multiplex (eBioscience) 
and by ELISA (System Biosciences, Mountain View, 
CA, USA). The following markers will be analyzed: 
interleukin-1, interleukin-6, interleukin-10, vascular 
cell adhesion molecule, tumor necrosis factor alpha, 
matrix metalloproteinase 9, VEGF, BDNF, anti-Nogo 
A.
Sample size estimates Based on data from previous 
studies [11, 25] and using the statistical software NCSS 
PASS 11 (NCSS, Utah, USA), we calculated that a sample 
of 10 rats per group will be required to achieve a power 
of 80% (1-beta) and a level of significance of 5% (alpha) to 
detect a significant effect of GV on the study endpoints.
Fig. 1 Experimental animal protocol. Hyperglycemia will be induced 72 h before surgery. The rats will then undergo a IS through permanent 
middle cerebral artery occlusion or sham surgery. Insulin treatment will be intravenously or subcutaneously administered 4 h after IS induction and 
up to 96 h later, after which the blood glucose levels will be continuously monitored. A functional evaluation will be performed at 24 h, 1 week 
and 4 weeks post‑stroke. Peripheral blood will be extracted 24 h, 72 h and 4 weeks after the stroke. The MRI will be analyzed at 24 h and 4 weeks 
post‑stroke. Four weeks after the stroke, the animals will be euthanized, and histological analyses will be performed
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Statistical analysis
The statistical analysis will be performed with advice 
from the Department of Biostatistics of La Paz Univer-
sity Hospital. For the continuous variables, the following 
information will be provided: number of participants, 
mean, standard deviation, median, minimums, maxi-
mums and 25% and 75% quartiles. For the categorical 
variables, the frequency distribution and 95% confidence 
interval (CI), if applicable, will be provided. The analysis 
of the prognostic influence of GV on stroke outcomes 
will be performed in an exploratory manner without 
assumptions. We will first analyze GV as a continuous 
variable, comparing it with primary and secondary end-
points using Student’s t-test or the Mann–Whitney U 
test, as appropriate. We will also compare GV according 
to the various insulin types and administration routes 
applied to the patients according to the physician’s dis-
cretion. The comparisons will be performed with the 
one-way analysis of variance test. Secondly, we will per-
form a step forward logistic regression analysis for the 
endpoints that achieved a difference with a P value < 0.1 
in the mean comparison tests, adjusting for age and base-
line National Institutes of Health Stroke Scale score. The 
results will be expressed as odds ratios (OR) with 95% CI. 
In case of lack of homogeneity in the variances, we will 
use non-parametric tests (Kruskal–Wallis and Mann–
Whitney test).
DIscussion
To our knowledge, few studies have used continuous glu-
cose monitors in acute IS [7, 8, 26–28]. A relationship has 
been found between GV (by means of the standard devi-
ation of mean glucose levels) and infarct growth [8], as 
well as between GV and early neurological deterioration 
[29]. The main limitations of the prior studies using CGM 
in acute stroke are their monocentric settings, the lack 
of analysis of the effect of insulin administration on GV 
and the heterogeneity in the index used to express GV, 
given there is no widely accepted optimal index [30]. The 
GLIAS-III study is designed to overcome those limita-
tions, with a prospective and multicenter approach, and 
is aimed at recruiting more than 300 patients. Moreover, 
the development of a parallel preclinical study using an 
animal model of permanent MCAO will increase our 
knowledge of the effect of insulin administration on 
GV, functional outcomes, lesion size, brain damage and 
repair-related markers.
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